Gf Fund Management Co. Ltd. Biocryst Pharmaceuticals Inc Transaction History
Gf Fund Management Co. Ltd.
- $4.62 Trillion
- Q4 2024
A detailed history of Gf Fund Management Co. Ltd. transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Gf Fund Management Co. Ltd. holds 4,349 shares of BCRX stock, worth $40,054. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,349Holding current value
$40,054% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BCRX
# of Institutions
278Shares Held
167MCall Options Held
728KPut Options Held
989K-
Vanguard Group Inc Valley Forge, PA21.9MShares$202 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$184 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.9MShares$109 Million1.3% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.09MShares$83.7 Million4.33% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY8.14MShares$75 Million1.52% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.71B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...